Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (73898)	11/19/1999 8:33:00 AM
From: kathyh	Respond to of 90042

imcl secondary priced... Friday November 19, 8:12 am Eastern Time Imclone prices offer of 2.75 mln shrs at $32 each NEW YORK, Nov 19 (Reuters) - ImClone Systems Inc. (NasdaqNM:IMCL - news), which specializes in developing cancer treatments, on Friday said it had priced its public offering of 2.75 million shares at $32 per share. ImClone will have about 28.4 million shares outstanding after the offering. It expects net proceeds of about $81.8 million, after underwriters' commissions and offering expenses, or $94.3 million if the underwriters exercise their over-allotment rights in full. ImClone has granted the underwriters an option to purchase an additional 412,500 shares to cover over-allotments. Managing underwriters are Morgan Stanley Dean Witter, Merrill Lynch & Co., Prudential Vector Healthcare Group, a unit of Prudential Securities, and Warburg Dillon Read LLC.